SPONSORED // 7 Min Read

Big Tech Wants a Piece of this Potential $658 Billion Global Medical Device Market…

Here’s Why that Could Hand BioSig Technologies Investors an Approx. 803% Payday

Major tech companies are aggressively moving into the medical device market.

Amazon, Meta Platforms, Apple, Alphabet….

All want a piece of a market that could be worth about $658 billion by 2028 – which could be a massive catalyst for medical device stocks like BioSig Technologies Inc. (NASDAQ: BSGM).

Consider this.

With medicine and healthcare having more of a grip on our everyday lives than ever before, interest and demand have skyrocketed in every aspect of the healthcare industry- especially the potential $625 Billion global medical device market. (2)

In fact, it has unequivocally sent massive shockwaves throughout the world.

So much so that corporate juggernauts like Amazon.com, Facebook, Alphabet Inc., and Apple Inc. are all trying to get involved with medical devices. (1)

Even better – a sub-sector of that booming medical device market is really gaining big momentum — cardio-focused medical devices.

And we’ve seen stocks with that niche focus pop considerably.

All saw a substantial run.

Another one to consider is BioSig Technologies Inc. (NASDAQ: BSGM), an underrated, under-the-radar, and potentially undervalued play that could very well follow in those stocks’ footsteps and with even more room to run.

Especially if it can revolutionize the way we treat heart problems – especially arrhythmias. 

According to the company:

"One in 18 Americans suffers from a cardiac arrhythmia. Atrial fibrillation is the most common arrhythmia type, affecting over 33 million people worldwide, including over 6 million in the U.S. The number of people suffering from atrial fibrillation is expected to reach 8-12 million by 20501. According to the Centers for Disease Control and Prevention (CDC), atrial fibrillation causes more than 750,000 hospitalizations in the U.S. each year, resulting in approximately $6 billion in healthcare spending annually"

Reason #1 - Perfect Positioning To Help Millions In a Potential $10.72 Billion (3) Boom

Let’s talk a bit more about arrhythmias.

According to the American Heart Association, arrhythmias occur when the heart’s electrical system malfunctions and causes the heart to beat too fast, too slow, or erratically. (Source 11)

While figures vary, it is probably way more common and a much larger market than you realize. For one, Dr. Juan Viles-Gonzalez, M.D., an electrophysiologist with Baptist Health’s Miami Cardiac & Vascular Institute, estimates over 60 million Americans suffer from it. (11)


“Two of the most prevalent, complex and potentially deadly types of arrhythmias today are Atrial Fibrillation (AF) and Ventricular Tachycardia (VT). Ventricular arrhythmias account for approximately 300,000 sudden deaths per year in the United States alone. Catheter ablation is fast becoming a first line therapy, driving demand for improved technologies. AF is the most common arrhythmia affecting 33.5 million people worldwide, with as many as 6.1 million people in the U.S. now and expected 8-12 million by 2050. AF increases the risk of stroke 4x to 5x and contributes to ~750,000 hospitalizations per year. The direct cost of AF is approximately $6B annually; adding other indirect costs brings AF total cost to $26B.” (12)

As also noted by the AHA, increased awareness and better diagnostic tools could help these millions of patients. Results can potentially help a doctor decide if you need medication, a pacemaker, a defibrillator, or cardiac ablation.

Fortunately, BioSig Technologies Inc. (NASDAQ:BSGM) exists and intends to make this happen while revolutionizing the entire process. 

BioSig is commercializing a biomedical signal processing platform. Designed to improve electrophysiology (EP), BioSig’s flagship product, PURE EP, is the key to the kingdom. 

PURE EP is a computerized system designed to reveal the full range of cardiac signals and provide physicians with signal clarity during procedures to address cardiac arrhythmias. 

Here’s the deal.

With that technology, BioSig has an enormous opportunity at hand in a Global Medical Devices Market that’s projected to reach $625.3 Billion by 2027 at a 6.3% CAGR. (2)

It could also very well be operating within the rapidly emerging field of bioelectronic medicine, estimated at $25.11 billion in 2020 with projected annual growth of 10.27%. (12)

Reason #2 - A Potentially Game-Changing Product

As mentioned above, BioSig’s PURE EP device is a computerized system designed to reveal the full range of cardiac signals. All while providing physicians with signal clarity during procedures performed to address cardiac arrhythmias. It aims to fill a significant need by (12)
This could be potentially groundbreaking and XTalks sums up best the vital need that PURE EP could fill:

“The electrograms used today can be riddled with noise and artifacts coming from other equipment found in the operating room. Such a procedure can take up to six hours, potentially yielding what is referred to in the industry as a ‘dirty signal’ that’s indiscernible to interpret by many electrophysiologists.” (14) 

BioSig’s PURE EP was developed to address unmet needs in a large and growing market. It also intends to deliver technology to improve catheter ablation treatments for arrhythmias, Atrial Fibrillation, and Ventricular Tachycardia.

“The system is intended to acquire, digitize, amplify, filter, measure and calculate, display, record and store electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory under the supervision of licensed healthcare practitioners who are responsible for interpreting the data,” as further reported XTalks.  (14) 

Furthermore, BioSig Technologies’ PURE EP boasts: (15)

Pure EP also combines advanced technologies and combines a range of proprietary hardware and software into a single platform. Its low-noise architecture, extensive dynamic range, and high-frequency bandwidth accurately capture the full range of cardiac signals with high fidelity. At the same time, customizable software modules and filters enable unlimited real-time analysis. (15)

It is also fully customizable and offers software modules and specialty digital filters, facilitating signal interpretation during mapping and therapy delivery.

Source 15

The best part? As next-gen and cutting-edge as it is, PURE EP seamlessly integrates with existing EP labs and workflows. It is fully compatible and complementary with EP recording systems, mapping systems, robotic equipment, and multi-display panels. (Source 15)

Is it any wonder why that….

Reason #3 - With Full FDA Clearance, (12) PURE EP’s Clinical Results Are Wowing The World- Prestigious Medical Centers Are Taking Notice

Since 2017, BioSig has had a noteworthy 10-year strategic agreement with the prestigious Mayo Clinic and Mayo Clinic Ventures. (Source 16) 

How things have escalated since. More than 70 physicians have completed over 1500 patient cases with the PURE EP System across thirteen clinical sites. (Source 13) 

And counting.

The successful clinical use of the PURE EP System was led by two globally recognized leaders:

Dr. Andrea Natale of Texas Cardiac Arrhythmia Institute (TCAI) and Prof. John M. Miller of Indiana University. BioSig also achieved proof of concept validation through UCLA and has performed twenty-one pre-clinical studies at Mayo Clinic, MN, under Samuel J. Asirvatham, M.D., Mayo Clinic’s Vice-Chair of Innovation and Medical Director, Electrophysiology Laboratory. (12) 

PURE EP Systems are also installed at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic’s Florida campus, Massachusetts General Hospital, the University of Pennsylvania, and Deborah Heart and Lung Center. (17) St. Elizabeth’s Medical Center in Boston (23) and Medical City North Hills in North Richland Hills, Texas (24) also recently signed on to evaluate it. 

A multi-center study at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital showed shocking clinical results.

It was seen as equivalent or superior to conventional systems for 93.6% of signal samples, with 75.2% earning a superior rating. ( 15)

“In order for any new medical technology to be widely adopted and accepted, strong, prospective clinical study results are necessary. The results from the PURE EP 2.0 study clearly validate the clinical importance of our technology and position the Company for continued growth and success.  We are grateful for the many physician investigators and research staff who participated in this study and look forward to continuing our clinical work to advance the field of electrophysiology and bioelectronic medicine,” said Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc. (8)

Reason #4 - With a $13 Price Target, Laidlaw and Company Could See 400+% of Potential Upside For The Stock... (26) A Tendency To Rally Rapidly Could Make BGSM The Value Play Of a Generation

The BSGM stock is well off its 2021 highs and record high of $12.43, which it reached on or around May 2020. (27)

From here, according to Laidlaw & Company, as of its most recent analyst report, the stock could have a $13 price target. (26) Based on its March 23, 2022 close of $1.44, that could give the stock upside potential north of about 803%.

To Sum It Up…

Stocks like BioSig Technologies (NASDAQ: BSGM) do not come around often.

To trade at under $1.44 (as of March 23), with exposure to surging in-demand industries, along with validation from some of the most respected medical facilities in the world, is generationally mouth-watering. 

We discussed some other stocks in the medical device industries that have had strong years. BioSig truly has all the ingredients necessary to potentially follow suit, and, shockingly, there’s an opportunity at hand to monitor this stock at such a potential discount. 

It has a potentially revolutionary product that could change the course of how we treat arrhythmias. It also has quality leadership, and most of all, outstanding projected net income growth and potentially 803% of room to run based on its $13 price target from Laidlaw & Company. (26) 

With Amazon, Facebook, and Google all wanting a piece of the medical device market, pay close attention to this under-the-radar disruptor. (Source 1)

It could truly be one of the wildest ground-floor breakouts we’ve ever seen.

Source 1: https://www.yahoo.com/now/10-medical-device-stocks-2021-204853768.html

Source 2: https://www.prnewswire.com/news-releases/medical-devices-market-size-worth-usd-625-3-billion-by-2027–cagr-6-3-astute-analytica-301404327.html

Source 3: https://www.globenewswire.com/news-release/2021/06/25/2253372/0/en/Electrophysiology-Devices-Market-Size-to-Surpass-Around-US-10-72-Bn-by-2027.html

Source 4: https://www.investopedia.com/articles/stocks/09/investing-medical-equipment-companies.asp#:~:text=Medical%20equipment%20companies%20offer%20investors,a%20growth%20or%20value%20investor
Source 5: https://finance.yahoo.com/quote/BIO/history?p=BIO

Source 6: https://finance.yahoo.com/quote/TMO/history?p=TMO

Source 7: https://finance.yahoo.com/quote/SYK/history?p=SYK

Source 8: https://finance.yahoo.com/quote/BSX/history?p=BSXSource 9: https://finance.yahoo.com/quote/EW/history/

Source 10: https://finance.yahoo.com/quote/ABMD/history?p=ABMD

Source 11: https://baptisthealth.net/baptist-health-news/heart-arrhythmias-afib-and-atrial-flutter-on-the-rise-in-u-s/

Source 12: https://d1io3yog0oux5.cloudfront.net/_269b3834a20423d95470d6e4877b861e/biosigtech/db/338/2433/pdf/BioSig_Fact+Sheet_4.07.20_.pdf

Source 13: https://ir.biosig.com/press-releases/detail/288/biosigs-pure-ep-system-to-be-featured-in-a-live-patient

Source 14: https://xtalks.com/biosigs-pure-ep-system-in-first-clinical-cases-1869/

Source 15: https://www.biosig.com/pure-ep/our-solution

Source 16: https://www.globenewswire.com/news-release/2017/03/17/940598/22558/en/BioSig-Technologies-Announces-Strategic-Partnership-with-Mayo-Clinic.html

Source 17: https://finance.yahoo.com/news/biosig-sees-increased-case-volume-222815099.html

Source 18: https://ir.biosig.com/press-releases/detail/287/clinical-data-acquired-by-the-pure-ep-system-published

Source 19: https://d1io3yog0oux5.cloudfront.net/biosigtech/files/docs/BioSig_PDF_Invite_10.11.21_%283%29.pdf

Source 20: https://ir.biosig.com/press-releases/detail/288/biosigs-pure-ep-system-to-be-featured-in-a-live-patient

Source 21: https://ir.biosig.com/press-releases

Source 22: https://ir.biosig.com/press-releases/detail/286/biosig-selects-plexus-corp-as-its-manufacturing-partner

Source 23: https://ir.biosig.com/press-releases/detail/284/biosig-increases-installation-footprint-adding-st

Source 24: https://ir.biosig.com/press-releases/detail/280/biosig-latest-installation-broadens-clinical-footprint-for

Source 25: https://ir.biosig.com/press-releases/detail/285/biosig-technologies-inc-appoints-medical-device-industry

Source 26: Laidlaw and Company Analyst Report Oct 4, 2021

Source 27: https://stockcharts.com/h-sc/ui

Source 28: https://finance.yahoo.com/quote/BSGM/key-statistics?p=BSGM

Source 29: https://finance.yahoo.com/quote/BSGM/history?p=BSGM

Source 30: https://finance.yahoo.com/news/biosig-signal-processing-technology-electrophysiology-134500015.html

Source 31: https://finbox.com/NASDAQCM:BSGM/explorer/ni_proj_growth

Source 32: Intro-Act Report

Source 33: Laidlaw Plexus Report

Discover More.

Sign up for news on more investor relations.